


## Suramin sodium salt

<b>Cat. No.:</b>	HY-B0879A
<b>CAS No.:</b>	129-46-4
<b>Molecular Formula:</b>	C <sub>51</sub> H <sub>34</sub> N <sub>6</sub> Na <sub>6</sub> O <sub>23</sub> S <sub>6</sub>
<b>Molecular Weight:</b>	1429.17
<b>Target:</b>	Phosphatase; Sirtuin; Reverse Transcriptase; Topoisomerase; Apoptosis; Parasite; SARS-CoV
<b>Pathway:</b>	Metabolic Enzyme/Protease; Cell Cycle/DNA Damage; Epigenetics; Anti-infection; Apoptosis
<b>Storage:</b>	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 83.33 mg/mL (58.31 mM; Need ultrasonic)  
H<sub>2</sub>O : 50 mg/mL (34.99 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	0.6997 mL	3.4985 mL	6.9971 mL
	5 mM	0.1399 mL	0.6997 mL	1.3994 mL
	10 mM	0.0700 mL	0.3499 mL	0.6997 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: PBS  
Solubility: 100 mg/mL (69.97 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.08 mg/mL (1.46 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.08 mg/mL (1.46 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

Suramin sodium salt (Suramin hexasodium salt) is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor<sup>[1]</sup>. Suramin sodium salt is a potent inhibitor of sirtuins: SirT1 (IC<sub>50</sub>=297 nM), SirT2 (IC<sub>50</sub>=1.15 μM), and SirT5 (IC<sub>50</sub>=22 μM)<sup>[2]</sup>. Suramin sodium salt is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC<sub>50</sub>=5 μM)<sup>[3][4]</sup>. Suramin sodium salt is a potent SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitor<sup>[5]</sup>. Suramin sodium salt efficiently inhibits IP5K and is an antiparasitic, anti-neoplastic and anti-angiogenic agent<sup>[6][7][8]</sup>.

IC <sub>50</sub> & Target	SIRT1 297 nM (IC <sub>50</sub> )	SIRT2 1.15 μM (IC <sub>50</sub> )	SIRT5 22 μM (IC <sub>50</sub> )																								
<b>In Vitro</b>	<p>Suramin sodium salt (Suramin hexasodium salt; 50-600 μg/mL; for 24-96 hours) inhibits cells proliferation in a dose-dependent and time-dependent manner and decreases viability in cancer cells<sup>[7]</sup>.</p> <p>Suramin sodium salt (300 μg/mL; for 48 hours) induces cells apoptosis and down-regulates mRNA expression in HeLa cells<sup>[7]</sup>.</p> <p>Suramin sodium salt (1 mg/mL; 1 hour) significantly suppresses the phosphorylated ERK1/2<sup>[8]</sup>.</p> <p>The IC<sub>50</sub> values of HO-8910 PM and HeLa are 319 μg/mL, 476 μg/mL, respectively<sup>[7]</sup>.</p> <p>Suramin blocks viral replication in Vero E6 cells<sup>[5]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay<sup>[6]</sup></p> <table border="1" data-bbox="345 554 1515 785"> <tr> <td>Cell Line:</td> <td>HO-8910 PM ovarian and Hela cervical cancer cells</td> </tr> <tr> <td>Concentration:</td> <td>50, 100, 200, 300, 400, 500 and 600 μg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>For 24, 48, 72 and 96 hours</td> </tr> <tr> <td>Result:</td> <td>Inhibited cells proliferation in a dose-dependent and time-dependent manner.</td> </tr> </table> <p>Apoptosis Analysis<sup>[6]</sup></p> <table border="1" data-bbox="345 856 1515 1087"> <tr> <td>Cell Line:</td> <td>HeLa cells</td> </tr> <tr> <td>Concentration:</td> <td>300 μg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>For 48 hours</td> </tr> <tr> <td>Result:</td> <td>Induced cells apoptosis.</td> </tr> </table> <p>Western Blot Analysis<sup>[7]</sup></p> <table border="1" data-bbox="345 1159 1515 1390"> <tr> <td>Cell Line:</td> <td>PA-SMCs cells</td> </tr> <tr> <td>Concentration:</td> <td>1 mg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>For 1 hour</td> </tr> <tr> <td>Result:</td> <td>Significantly suppressed the phosphorylated ERK1/2.</td> </tr> </table>			Cell Line:	HO-8910 PM ovarian and Hela cervical cancer cells	Concentration:	50, 100, 200, 300, 400, 500 and 600 μg/mL	Incubation Time:	For 24, 48, 72 and 96 hours	Result:	Inhibited cells proliferation in a dose-dependent and time-dependent manner.	Cell Line:	HeLa cells	Concentration:	300 μg/mL	Incubation Time:	For 48 hours	Result:	Induced cells apoptosis.	Cell Line:	PA-SMCs cells	Concentration:	1 mg/mL	Incubation Time:	For 1 hour	Result:	Significantly suppressed the phosphorylated ERK1/2.
	Cell Line:	HO-8910 PM ovarian and Hela cervical cancer cells																									
	Concentration:	50, 100, 200, 300, 400, 500 and 600 μg/mL																									
	Incubation Time:	For 24, 48, 72 and 96 hours																									
	Result:	Inhibited cells proliferation in a dose-dependent and time-dependent manner.																									
	Cell Line:	HeLa cells																									
	Concentration:	300 μg/mL																									
	Incubation Time:	For 48 hours																									
	Result:	Induced cells apoptosis.																									
	Cell Line:	PA-SMCs cells																									
	Concentration:	1 mg/mL																									
	Incubation Time:	For 1 hour																									
Result:	Significantly suppressed the phosphorylated ERK1/2.																										
<b>In Vivo</b>	<p>Suramin sodium salt (Suramin hexasodium salt; 10 mg/kg; IV; twice weekly for 3 weeks) reverses established pulmonary hypertension (PH), thereby normalizing the pulmonary artery pressure values and vessel structure<sup>[8]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>																										
	Animal Model:	Adult male Wistar rats (200-225 g) <sup>[7]</sup>																									
	Dosage:	10 mg/kg																									
	Administration:	IV; twice weekly for 3 weeks																									
	Result:	Reversed established PH, thereby normalizing the pulmonary artery pressure values and vessel structure.																									

- Nat Struct Mol Biol. 2021 Mar;28(3):319-325.
- Clin Transl Med. 2021 Jun;11(6):e485.
- Int Immunopharmacol. 2023 May 12;120:110295.
- J Biol Chem. 2021 Sep 3;101166.
- J Biol Chem. 2020 Jul 24;295(30):10281-10292.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

- [1]. Xiaozhe Zhang, et al. Suramin and NF449 Are IP5K Inhibitors That Disrupt IP6-mediated Regulation of Cullin RING Ligase and Sensitize Cancer Cells to MLN4924/pevonedistat. J Biol Chem. 2020 Jun 3;jbc.RA120.014375.
- [2]. Jindal HK, et al. Suramin affects DNA synthesis in HeLa cells by inhibition of DNA polymerases. Cancer Res. 1990 Dec 15;50(24):7754-7.
- [3]. Izikki M, et al. The beneficial effect of suramin on monocrotaline-induced pulmonary hypertension in rats. PLoS One. 2013 Oct 15;8(10):e77073.
- [4]. Zhang YL, et al. Suramin is an active site-directed, reversible, and tight-binding inhibitor of protein-tyrosine phosphatases. J Biol Chem. 1998 May 15;273(20):12281-7.
- [5]. Trapp J, et al. Structure-activity studies on suramin analogues as inhibitors of NAD<sup>+</sup>-dependent histone deacetylases (sirtuins). ChemMedChem. 2007 Oct;2(10):1419-31.
- [6]. Schuetz A, et al. Structural basis of inhibition of the human NAD<sup>+</sup>-dependent deacetylase SIRT5 by suramin. Structure. 2007 Mar;15(3):377-89.
- [7]. De Clercq E, et al. Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses. Cancer Lett. 1979 Nov;8(1):9-22.
- [8]. Novaes RD, et al. Purinergic Antagonist Suramin Aggravates Myocarditis and Increases Mortality by Enhancing Parasitism, Inflammation, and Reactive Tissue Damage in Trypanosoma cruzi-Infected Mice. Oxid Med Cell Longev. 2018 Sep 30;2018:7385639.
- [9]. Wanchao Yin, et al. Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin. Nat Struct Mol Biol. 2021 Mar;28(3):319-325.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA